

- 7.11 (a) Upon receiving a request by an *Athlete* for review, the *WADA TUEC* will, as specified in Article 4.4 of the *Code*, be able to reverse a decision on a TUE denied by an *Anti-Doping Organization*. The *Athlete* shall provide to the *WADA TUEC* all the information for a TUE as submitted initially to the *Anti-Doping Organization* accompanied by an application fee. Until the review process has been completed, the original decision remains in effect. The process should not take longer than thirty (30) days following receipt of all the information by *WADA*.
- (b) *WADA* can, on its own initiative, undertake a review at any time.
- 7.12 If the decision regarding the granting of a TUE is reversed by *WADA* upon review, the reversal shall not apply retroactively and shall not disqualify the *Athlete's* results during the period that the TUE had been granted and shall take effect no later than fourteen (14) days following notification of the decision to the *Athlete*.
- 7.13 Use of inhaled Beta-2 Agonists:
- The *Use* of inhaled formoterol, salbutamol, salmeterol, terbutaline reflects current clinical practice. The *Use* of these substances should be declared on *ADAMS* where reasonably feasible and in accordance with the *Code* as soon as the product is used and must as well be declared on the *Doping Control* form at the time of *Testing*. Failure to declare will be taken into account in the result management process in particular in case of application for a Retroactive TUE.
 - *Athletes* using the substances listed above by inhalation must have a medical file justifying this *Use* and meeting the minimum requirements outlined in Annex I.

Depending upon the category of the *Athlete*, the medical file will be evaluated as follows:

- For all *Athletes* included in an International Federation *Registered Testing Pool* a regular TUE approved before the *Use* of the substance.